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ABSTRACT	
	
Metastatic	infection	is	an	important	complication	of	Staphylococcus	aureus	bacteremia	(SAB).	Early	diagnosis	
of	metastatic	infection	is	crucial,	as	specific	treatment	is	required.	However,	metastatic	infection	can	be	
asymptomatic	and	difficult	to	detect.	In	this	study,	we	investigated	the	role	of	18F‐FDG‐PET/CT	in	patients	
with	SAB	for	detection	of	metastatic	infection	and	its	consequences	for	treatment	and	outcome.	
Methods	
All	patients	with	SAB	at	Radboud	university	medical	center	were	included	between	January	2013	and	April	
2016.	Clinical	data	and	results	of	18F‐FDG‐PET/CT	and	other	imaging	techniques,	including	echocardiography,	
were	collected.	Primary	outcomes	were	newly	diagnosed	metastatic	infection	by	18F‐FDG‐PET/CT,	subsequent	
treatment	modifications,	and	outcome.	
Results	
A	total	of	184	patients	were	included	and	18F‐FDG‐PET/CT	was	performed	in	105	patients	of	whom	99	had	a	
high‐risk	bacteremia.	18F‐FDG‐PET/CT	detected	metastatic	infectious	foci	in	73.7%	of	these	high‐risk	patients.	
In	71.2%	of	patients	with	metastatic	infection,	no	signs	and	symptoms	suggesting	metastatic	complications	
were	present	before	18F‐FDG‐PET/CT	was	performed.	18F‐FDG‐PET/CT	led	to	a	total	of	104	treatment	
modifications	in	74	patients.	Three‐month	mortality	was	higher	in	high‐risk	bacteremia	patients	without	18F‐
FDG‐PET/CT	performed	compared	to	those	in	whom	18F‐FDG‐PET/CT	was	performed	(32.7%	versus	12.4%,	
p=0.003).	In	multivariate	analysis,	18F‐FDG‐PET/CT	was	the	only	factor	independently	associated	with	
reduced	mortality	(p=0.005;	OR,	0.204;	95%	CI,	0.066‐0.624).	A	higher	co‐morbidity	score	was	independently	
associated	with	increased	mortality	(p=0.003;	OR,	1.254;	95%	CI,	1.078‐1.457).	
Conclusion	
18F‐FDG‐PET/CT	is	a	valuable	technique	for	early	detection	of	metastatic	infectious	foci,	often	leading	to	
treatment	modification.	Performing18F‐FDG‐PET/CT	is	associated	with	significantly	reduced	three‐month	
mortality.	
	
Keywords:	18F‐FDG‐PET/CT,	Staphylococcus	aureus,	metastatic	infection		 	
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INTRODUCTION	
SAB	is	a	severe	infection	known	for	its	high	morbidity	and	is	associated	with	a	30‐day	overall	
mortality	of	20%	(1).	An	important	complication	of	SAB	is	metastatic	infection,	with	a	reported	incidence	
between	16	and	68%	(2‐7).	Known	risk	factors	for	development	of	metastatic	infection	in	SAB	patients	are	
community	acquisition	of	the	bacteremia,	signs	of	infection	present	for	more	than	48	hours	before	initiation	of	
appropriate	antibiotic	treatment,	fever	more	than	72	hours	after	initiation	of	appropriate	antibiotic	treatment,	
and	positive	blood	cultures	more	than	48	hours	after	initiation	of	appropriate	antibiotic	treatment	(3).	Early	
detection	of	metastatic	infection	is	crucial,	as	morbidity	and	mortality	are	higher	in	the	presence	of	these	foci,	
probably	due	to	incomplete	eradication	during	treatment	(8).	However,	metastatic	infectious	foci	are	often	
asymptomatic.	In	up	to	one‐third	of	patients	with	Gram‐positive	bacteremia	and	metastatic	foci,	localizing	
signs	and	symptoms	are	absent	(8).		
	 During	the	past	years,	18F‐fluorodeoxyglucose	positron	emission	tomography	combined	with	
computed	tomography	(18F‐FDG‐PET/CT)	has	been	extensively	used	in	diagnosing	infectious	diseases.	
Previous	studies	on	the	value	of	18F‐FDG‐PET/CT	in	metastatic	infection	have	demonstrated	that	18F‐FDG‐
PET/CT	detects	infectious	foci	in	patients	with	bacteremia	or	infective	endocarditis	and	leads	to	a	decrease	in	
relapse	and	mortality	rate	(9,10).	Furthermore,	18F‐FDG‐PET/CT	has	shown	to	be	cost‐effective	in	patients	
with	Gram‐positive	bacteremia	(11).	The	previous	studies,	however,	did	not	report	on	how	18F‐FDG‐PET/CT	
optimizes	treatment	in	SAB,	while	the	positive	effect	on	outcome	is	undoubtedly	caused	by	treatment	
modification.	Therefore,	the	aim	of	this	study	was	to	investigate	the	diagnostic	value	of	18F‐FDG‐PET/CT	for	
newly	diagnosed	metastatic	infection,	subsequent	treatment	modifications,	and	outcome	in	patients	with	SAB,	
with	a	focus	on	patients	with	high‐risk	bacteremia.	
	 	
by Universiteitsbibliotheek Nijmegen on March 27, 2017. For personal use only. jnm.snmjournals.org Downloaded from 
4 
 
MATERIALS	AND	METHODS	
	
Study	design	and	patients	
	 This	retrospective	cohort	study	was	performed	at	Radboud	university	medical	center,	Nijmegen,	the	
Netherlands.	All	consecutive	adult	SAB	cases	between	January	2013	and	April	2016	were	included.	SAB	was	
defined	as	one	or	more	blood	cultures	positive	for	S.	aureus.	SAB	cases	were	designated	hospital‐acquired	if	
patients	had	been	admitted	for	at	least	48	hours	before	the	first	positive	blood	culture,	or	as	community	
acquired	in	all	other	cases.	Exclusion	criteria	were	pregnancy,	and	death	within	48	hours	after	the	first	
positive	blood	culture	with	S.	aureus.	According	to	the	Dutch	law,	this	study	was	exempt	from	approval	by	an	
ethics	committee,	because	of	the	retrospective	character	of	this	study	and	the	anonymous	processing	of	data. 
The	regional	institutional	review	board	approved	this	retrospective	study	and	the	requirement	to	obtain	
informed	consent	was	waived.	
	
Data	collection		
	 We	reviewed	the	medical	records	of	all	patients	and	collected	data	on	patient	demographic	
characteristics,	estimated	prognosis	of	preexisting	underlying	disease	and	comorbidity	according	to	the	
Charlson	comorbidity	score	(12),	onset	of	bacteremia,	presence	of	intravascular	catheters	or	foreign	body	
material,	resistance	of	S.	aureus	to	methicillin,	foci	of	infection,	and	clinical	parameters	at	SAB	onset,	
diagnostic	investigations,	antimicrobial	therapy,	and	outcomes.	The	data	were	retrieved	electronically	from	
clinical	charts	and	reports	of	diagnostic	studies	(including	laboratory,	microbiological	and	imaging	data).		
	
Diagnostic	work‐up	
	 According	to	definitions	established	previously	(3,8),	cases	were	designated	high‐risk	SAB	if	one	of	
the	following	criteria	for	increased	risk	of	metastatic	infection	were	met:	community	acquisition	of	the	
bacteremia,	signs	of	infection	for	more	than	48	hours	before	initiating	of	appropriate	antibiotic	treatment,	
fever	more	than	72	hours	after	initiating	of	appropriate	antibiotic	treatment,	positive	blood	cultures	more	
than	48	hours	after	initiating	of	appropriate	antibiotic	treatment,	or	already	confirmed	metastatic	foci	at	the	
moment	of	presentation.	For	all	patients	with	high‐risk	SAB,	echocardiography	and	18F‐FDG‐PET/CT	were	
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recommended.		
	 An	integrated	PET/CT	scanner	(Biograph	40	mCT;	Siemens	Healthcare)	was	used.	Before	18F‐FDG	
injection,	patients	fasted	and	any	glucose	or	insulin‐containing	infusions	were	discontinued	for	at	least	six	
hours.	In	66.7%	of	patients,	a	low	carbohydrate	fat‐allowed	diet	was	performed	24	hours	before	18F‐FDG‐
PET/CT.	Blood	glucose	samples	were	taken	from	all	patients	prior	to	18F‐FDG	administration.	At	the	time	of	
18F‐FDG	injection,	glucose	was	below	12	mmol/l	in	all	patients,	including	diabetic	patients.	One	hour	after	
intravenous	injection	of	an	average	dosage	of	3.3	MBq	x	body	weight	(kg)/min/bed	position	18F‐FDG	
(Mallinckrodt	Pharmaceuticals,	Petten,	The	Netherlands	or	IBA	Molecular,	Amsterdam,	The	Netherlands),	a	
whole	body	low‐dose	CT	was	acquired	for	anatomic	correlation	and	attenuation	correction	of	the	PET	data.	
Emission	images	of	the	same	area	were	acquired.	18F‐FDG‐PET/CT	scans	were	considered	abnormal	if	focal	
accumulation	of	18F‐FDG	was	detected.	Normal	test	results	were	considered	true‐negative	when	no	
complicating	infectious	foci	were	diagnosed	within	two	weeks	after	18F‐FDG‐PET/CT	was	performed.	Normal	
test	results	were	considered	false‐negative	when	a	localized	infectious	focus	was	diagnosed	but	not	reported	
on	18F‐FDG‐PET/CT.	Abnormal	test	results	not	related	to	metastatic	infection	that	were	caused	by	a	confirmed	
alternative	diagnosis	(i.e.	cancer)	were	categorized	as	non‐infectious	relevant.		
	 In	all	patients	with	SAB,	the	local	antimicrobial	stewardship	program	recommends	bedside	
consultation	by	an	infectious	disease	specialist	(ID	specialist),	as	well	as	echocardiography.	Transthoracic	
echocardiography	(TTE)	was	used	as	a	first‐line	screening	technique,	except	for	those	patients	with	prosthetic	
valves,	in	whom	transesophageal	echocardiography	(TEE)	was	the	first‐line	technique.	TEE	was	
recommended	in	all	patients	in	whom	TTE	was	negative	for	endocarditis,	especially	when	imaging	was	
hampered	by	technical	or	anatomical	problems.	Endocarditis	was	defined	according	to	the	modified	Duke	
criteria	(13).		
	 Patients	were	treated	according	to	the	national	guideline	for	SAB	which	is	concordant	with	the	IDSA	
guideline	(14).	However,	for	patients	with	risk	factors	for	metastatic	foci	but	without	evidence	of	endocarditis	
after	echocardiography	and	without	signs	of	metastatic	infection	on	18F‐FDG‐PET/CT,	the	institutional	
guideline	recommends	antimicrobial	therapy	for	two	weeks.	These	patients	were	considered	as	having	
uncomplicated	bacteremia	instead	of	complicated	bacteremia.		
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Diagnosis	and	patient	follow‐up	
	 Patient	outcome	and	recurrent	infection	were	assessed	by	reviewing	patients’	medical	records	.	
Patient	follow‐up	after	end	of	antimicrobial	therapy	was	at	least	three	months	in	order	to	capture	SAB	relapse,	
mortality,	and	cause	of	death.	Patients	were	considered	to	be	cured	if	no	symptoms	or	signs	of	infection	were	
present	three	months	after	the	discontinuation	of	antibiotic	treatment.	Relapse	of	SAB	was	defined	as	a	
second	episode	of	SAB	within	three	months	after	end	of	treatment.	
	
18F‐FDG‐PET/CT	and	treatment	modifications	 	
	 The	impact	of	18F‐FDG‐PET/CT	on	treatment	was	determined	by	the	investigators	for	all	cases	in	a	
two	step	approach.	First,	treatment	duration	was	determined	based	on	all	clinical	information	available	before	
18F‐FDG‐PET/CT	was	performed.	Second,	the	results	of	the	18F‐FDG‐PET/CT	were	provided,	and	the	
modifications	of	therapy	based	on	these	results	were	noted.	During	a	weekly	multidisciplinary	meeting,	all	
results	of	18F‐FDG‐PET/CT	scans	performed	in	patients	with	SAB	were	discussed	with	a	panel	of	ID	specialist	
and	nuclear	medicine	physicians	and	treatment	modifications	based	on	these	results	were	also	noted	in	the	
patient’s	chart.	
	 The	impact	of	18F‐FDG‐PET/CT	on	treatment	was	classified	as	follows:	1)	extension	of	antibiotic	
treatment	including	1a)	prolonged	intravenous	antibiotic	therapy,	e.g.	instead	of	oral	antibiotic	therapy,	1b)	
addition	of	a	second	antimicrobial	drug,	e.g.	rifampin	in	patients	with	foreign	body	material	infection,	or	1c)	
extension	of	total	treatment	duration,	e.g.	in	case	of	joint	or	vascular	prosthesis	infection,	2)	surgical	or	
radiological	intervention,	e.g.	abscess	drainage,	removal	of	foreign	body	material,	and	3)	shortening	of	
treatment	duration.	If	the	results	of	the	18F‐FDG‐PET/CT	did	not	result	in	any	intervention,	this	was	also	
reported.	To	prevent	interpretation	bias,	two	independent	physician	observers	(MAHB	and	IJEK)	reviewed	
hospitalization	records	and	determined	treatment	modification	before	and	after	18F‐FDG‐PET/CT	results.	If	
there	was	no	consensus,	a	third	independent	infectious	disease	specialist	(CPBR)	with	broad	experience	in	
SAB	and	18F‐FDG‐PET/CT	made	the	final	judgment.	In	patients	with	high‐risk	SAB,	a	comparison	was	made	
between	patients	who	underwent	18F‐FDG‐PET/CT	and	patients	who	did	not.		
	
Statistical	analysis	
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	 SPSS	(version	22.0;	SPSS,	Inc.)	was	used	for	analyzing	data.	Descriptive	statistics	for	continuous	
variables	were	represented	as	median	+/‐	standard	deviation.	Unpaired	student’s	t	tests	were	used	to	
compare	continuous	variables.	Categorical	variables	were	compared	by	use	of	the	chi‐square	test	or	Fisher’s	
exact	test	when	the	chi‐square	test	was	not	appropriate.	Differences	were	considered	to	be	statistically	
significant	at	a	two‐sided	p‐value	of	<0.05.	To	determine	independent	predictors	of	three‐month	mortality	in	
the	high‐risk	bacteremia	group,	we	performed	a	multivariate	analysis,	including	prognostic	factors	associated	
with	a	p‐value	<0.20	in	univariate	analysis.	To	limit	the	amount	of	variables	in	the	model,	the	Charlson	
comorbidity	score	was	used	as	a	composite	variable	for	age	and	co	morbidity.	As	a	composite	variable	for	risk‐
factors	for	metastatic	infection,	a	risk	score	previously	described	by	Fowler	et	al	(3)	was	used;	community‐
acquisition,	persistent	fever	>72	hours,	and	skin	findings	suggesting	the	presence	of	metastatic	infection	were	
separately	scored	as	1	point,	and	positive	follow‐up	blood	culture	results	were	scored	as	2	points.		
	
RESULTS		 	
	
	 During	the	study	period,	195	events	of	SAB	were	identified.	A	total	of	11	patients	(5.6%)	were	
excluded:	6	patients	died	within	48	hours,	and	5	patients	were	lost	to	follow‐up.	A	total	of	184	patients	were	
included	in	the	final	analysis.	Of	these,	148	(80.0%)	had	≥1	risk	factor	for	metastatic	infection,	and	were	
classified	as	high‐risk	SAB.	18F‐FDG‐PET/CT	was	performed	in	99	of	148	(66.9%)	high‐risk	SAB	cases.	In	
addition,	18F‐FDG‐PET/CT	was	performed	in	6	of	36	(16.7%)	patients	without	risk	factors	for	metastatic	
infection.	
Definite	endocarditis	according	to	the	modified	Duke	criteria	was	diagnosed	in	16	patients	(8.7%).	
Forty‐six	patients	(25.0%)	were	admitted	to	the	ICU	within	24	hours	before	and	one	week	after	SAB	onset.	Of	
184	S.	aureus	strains	isolated,	only	5	(2.7%)	were	methicillin‐resistant.	Central	venous	catheter	infection	was	
considered	responsible	for	35	episodes	(19.0%)	of	SAB.	Baseline	characteristics	of	all	patients	with	and	
without	18F‐FDG‐PET/CT	are	shown	in	Table	1.		
	
Detection	of	metastatic	infection	by	18F‐FDG‐PET/CT	
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	 18F‐FDG‐PET/CT	was	performed	in	105	of	184	study	patients	at	a	median	of	8.0	days	(mean	8.7	days)	
after	the	first	blood	culture	became	positive.	In	5	of	6	patients	without	risk	factors	for	metastatic	infection	in	
whom	18F‐FDG‐PET/CT	was	performed,	no	metastatic	infection	was	found	on	18F‐FDG‐PET/CT.	In	one	patient	
with	a	history	of	portal	vein	thrombosis,	without	risk	factors	for	metastatic	infection	and	removal	of	a	central	
venous	catheter	one	day	after	positive	blood	cultures,	an	18F‐FDG‐PET/CT	was	performed	and	detected	septic	
thrombophlebitis.	This	patient	received	intravenous	antibiotic	treatment	for	6	weeks.	18F‐FDG‐PET/CT	
detected	metastatic	infectious	foci	in	73	of	99	patients	with	high‐risk	bacteremia	(73.7%).	In	52	out	of	these	
73	patients	(71.2%)	eventually	diagnosed	with	metastatic	infection,	no	signs	and	symptoms	suggesting	
metastatic	complications	were	present	before	18F‐FDG‐PET/CT	was	performed.	Metastatic	infection	was	most	
often	diagnosed	in	the	lungs,	skin	and	soft	tissue,	and	as	osteoarticular	foci	(Table	2).	Of	all	73	patients	with	
metastatic	infection,	47	patients	(64.4%)	were	diagnosed	with	metastatic	foci	in	more	than	one	organ	system.	
Eighteen	patients	had	increased	18F‐FDG	uptake	in	a	cardiac	valve	suspected	for	endocarditis,	of	whom	5	had	a	
definite	endocarditis	according	to	the	modified	Duke	criteria,	10	had	a	possible	endocarditis,	and	in	3	patients	
the	diagnosis	of	endocarditis	was	rejected.		
	
Patient	outcome	
	 The	relapse	rate	three	months	after	treatment	discontinuation	was	2.2%	(4/184).	Overall	three‐
month	mortality	was	18.5%	(34/184).	In	the	univariate	analysis,	age	(59	versus	69	years,	p	<0.05),	intensive	
care	admission	(22.0%	versus	38.2%,	p	<0.05),	Charlson	comorbidity	score	(4.3	versus	6.5,	p	<0.05),	and	no	
18F‐FDG‐PET/CT	performed	(38.0%	versus	64.7%,	p=0.005)	were	significantly	different	between	survivors	
and	non‐survivors.		
	
Patients	with	risk	factors	for	metastatic	infection	
	 The	group	with	a	risk	factor	for	metastatic	infection	who	did	not	undergo	18F‐FDG‐PET/CT	
(Risk+/PET‐)	was	compared	with	the	group	of	patients	with	a	risk	factor	for	metastatic	infection	and	a	18F‐
FDG‐PET/CT	performed	(Risk+/PET+)	(Table	3).	In	patients	with	risk	factors	for	metastatic	infection	in	whom	
an	18F‐FDG‐PET/CT	was	performed,	three‐month	mortality	was	significantly	lower	compared	to	the	
'Risk+/PET‐'	group	(12.1%	versus	32.7%,	p=0.003).	Multivariate	analysis	of	risk	factors	for	three‐month	
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mortality	in	the	high‐risk	group	is	shown	in	Table	4.	18F‐FDG‐PET/CT	was	the	only	factor	that	was	
significantly	associated	with	reduced	mortality	(p=0.005;	OR,	0.204;	95%	confidence	interval	(CI),	0.066‐
0.624).	A	higher	co‐morbidity	score	was	significantly	associated	with	increased	mortality	(p=0.003;	OR,	1.254;	
95%	CI,	1.078‐1.457).	
	
Treatment	modifications	in	high‐risk	patients	
	 In	the	99	patients	with	high‐risk	SAB	who	underwent	18F‐FDG‐PET/CT,	104	treatment	modifications	
were	made	in	74	patients	(74.7%)	after	the	results	of	18F‐FDG‐PET/CT	became	available	(Table	5).	In	22	
patients	(22.2%),	more	than	one	treatment	modification	was	made.	In	25	patients	(25.3%),	treatment	
duration	was	shortened	because	no	metastatic	infection	was	detected.	In	15	patients	(15.2%),	intravenous	
antibiotic	therapy	was	prolonged	based	on	the	18F‐FDG‐PET/CT	results,	in	10	patients	(10.1%)	a	second	
antimicrobial	drug	was	prescribed,	and	in	35	patients	(35.4%),	the	total	treatment	duration	was	extended.	In	
most	cases,	treatment	was	extended	because	of	bone	or	joint	involvement	(22.2%),	vascular	prosthesis	
infection	(19.4%),	or	other	endovascular	infection	(17%).	Percutaneous	or	surgical	drainage	was	performed	
in	19	patients	(19.2%)	based	on	the	outcome	of	18F‐FDG‐PET/CT	(Fig.	1	and	Fig.	2).	No	treatment	modification	
was	made	in	25	patients	(25.3%)	(Table	5).		
	 Of	all	patients	with	a	planned	treatment	duration	of	6	weeks	or	more	before	18F‐FDG‐PET/CT	was	
performed,	one	or	more	treatment	modifications	were	performed	in	23	out	of	46	patients	(50.0%)	based	on	
18F‐FDG‐PET/CT	results	(Fig.	3),	compared	to	51	out	of	53	(96.2%)	in	the	group	with	a	planned	treatment	
duration	of	less	than	6	weeks.		
The	following	relevant	diseases	not	related	to	SAB	were	diagnosed	in	7	patients	(7.1%):	pulmonary	
carcinoma,	mediastinal	carcinoid	tumour,	recurrent	adenocarcinoma	of	the	rectum,	recurrent	vaginal	
carcinoma,	benign	thyroid	adenoma,	inflammatory	bowel	disease,	and	esophageal	candidiasis.	Irrelevant	
findings	were	found	in	8	patients:	in	these	patients	two	colonoscopies,	three	esophago‐gastro‐
duodenoscopies,	three	ultrasounds,	and	one	CT‐scan	were	performed	without	a	clear	diagnosis.		
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DISCUSSION	
	
	 In	this	study,	we	investigated	the	value	of	18F‐FDG‐PET/CT	in	patients	with	SAB	for	detecting	
metastatic	infection	and	its	role	in	treatment	modification	in	these	patients.	In	a	previous	prospective	study	
on	115	patients	with	high‐risk	Gram‐positive	bacteremia	(9),	the	addition	of	18F‐FDG‐PET/CT	to	standard	care	
led	to	significantly	more	patients	who	were	diagnosed	with	metastatic	infection	compared	to	a	matched	
historical	control	group	of	230	patients	in	whom	no	18F‐FDG‐PET/CT	was	performed	(67.8%	versus	35.7%	in	
the	control	group).	Furthermore,	six‐month	mortality	rate	decreased	from	32.2%	to	19.1%	when	18F‐FDG‐
PET/CT	was	performed.	An	explanation	for	the	slightly	higher	detection	level	in	our	study	(73.7%)	could	be	
the	fact	that	metastatic	infection	is	more	often	seen	in	SAB	than	in	other	types	of	Gram‐positive	bacteremia.	
Another	study	on	the	value	of	18F‐FDG‐PET/CT	for	the	diagnosis	of	metastatic	infection	in	47	patients	with	
infectious	endocarditis	found	that	18F‐FDG‐PET/CT	was	associated	with	a	twofold	reduction	in	the	number	of	
relapses	and	18F‐FDG‐PET/CT	enabled	significantly	more	infectious	complications	to	be	diagnosed	(57.4%	
versus	18%	in	matched	controls)	(10).	Orvin	et	al.	(15)	prospectively	studied	the	value	of	18F‐FDG‐PET/CT	in	
40	consecutive	patients	with	definite	endocarditis	according	to	the	Duke	criteria.	18F‐FDG‐PET/CT	
demonstrated	extracardiac	complications	in	17	patients	(42.5%),	and	these	findings	led	to	a	change	of	
treatment	in	14	patients	(35%)	while	these	patients	already	had	an	indication	for	prolonged	antibiotic	
treatment	because	of	endocarditis.	This	is	comparable	to	our	results,	as	treatment	was	still	adapted	in	50%	of	
patients	with	an	indication	for	prolonged	treatment	before	18F‐FDG‐PET/CT	was	performed.	
In	the	present	study,	the	early	detection	of	metastatic	infectious	foci	facilitated	the	adaptation	of	
treatment	in	patients	at	high	risk	of	relapse.	The	three‐month	relapse	rate	was	only	2.2%,	which	is	low	
compared	to	the	rates	reported	in	the	literature	for	complicated	SAB	(2.1‐23%)	(16).	An	important	finding	of	
the	present	study	is	that	patients	with	risk	factors	for	metastatic	infection	who	did	not	undergo	18F‐FDG‐
PET/CT	had	a	significantly	higher	mortality	rate	compared	to	those	who	underwent	18F‐FDG‐PET/CT	(32.7%	
versus	12.1%,	p=0.003),	even	though	the	average	number	of	risk	factors	for	metastatic	infection	in	the	latter	
group	was	higher.	This	emphasizes	the	importance	of	the	risk	assessment	for	metastatic	infection,	and	
suggests	that	physicians	should	not	refrain	from	ordering	18F‐FDG‐PET/CT	with	high‐risk	SAB	based	on	
personal	judgment.	Early	death	may	be	hypothesized	to	be	a	confounding	factor,	as	those	patients	were	
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unable	to	undergo	18F‐FDG‐PET/CT.	However,	in	a	sensitivity	analysis	excluding	patients	who	died	within	
seven	days	after	admission,	the	results	regarding	three‐month	mortality	were	similar.	Another	potential	
confounder	could	be	the	difference	in	ID	specialist	consultation,	because	ID	consults	have	been	associated	
with	reduced	mortality	in	patients	with	SAB	(5,17‐21).	However,	multivariate	logistic	regression	analysis	did	
not	show	this	to	be	an	independent	predictor	of	survival,	probably	due	to	the	high	frequency	of	ID	
consultation	in	both	groups	in	the	present	study.	In	our	study,	18F‐FDG‐PET/CT	detected	endocarditis	in	18	
patients	and	was	the	first	imaging	technique	detecting	endocarditis	in	11	patients.	In	contrary,	8	patients	were	
diagnosed	with	a	definite	endocarditis	according	to	the	modified	Duke	criteria	but	had	a	negative	18F‐FDG‐
PET/CT.	Whether	18F‐FDG‐PET/CT	could	be	used	for	diagnosing	native	valve	endocarditis	needs	further	
investigation,	as	small	studies	performed	on	this	subject	show	limited	evidence	(22).		
Our	study	has	several	limitations.	First,	this	is	a	single‐center	study	that	was	not	prospectively	
conducted.	In	26.6%	of	patients,	18F‐FDG‐PET/CT	was	indicated	but	not	performed.	The	reasons	for	non‐
adherence	to	the	local	guidelines	are	not	known,	and	this	could	potentially	have	led	to	selection	bias.	Second,	
although	we	used	a	two‐reviewer	adjudication	process	to	determine	treatment	modification,	it	is	possible	that	
misclassification	occurred.	To	reduce	bias,	the	two	reviewers	were	blinded	from	each	other	and	
disagreements	were	resolved	by	a	third	experienced	reviewer.		
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CONCLUSION	
	 In	conclusion,	performance	of	18F‐FDG‐PET/CT	is	significantly	associated	with	reduced	mortality	in	
patients	with	high‐risk	SAB,	and	leads	to	the	detection	of	metastatic	infectious	foci	in	73.7%	of	patients,	
resulting	in,	important	treatment	modifications.	18F‐FDG‐PET/CT	should	be	recommended	as	standard	
imaging	technique	for	all	patients	with	≥1	risk	factor	for	metastatic	infection	in	SAB	guidelines.		
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FIGURE	LEGENDS	
	
FIGURE	1.	Transversal	18F‐FDG‐PET/CT	images	at	the	level	of	the	celiac	trunk	(left)	and	maximum	intensity	
projection	(MIP)	image	(right)	of	a	60‐year‐old	man	who	was	admitted	because	of	a	septic	arthritis	of	his	right	
knee.	Blood	cultures	grew	methicillin‐susceptible	Staphylococcus	aureus.	A	transesophageal	echocardiography	
was	negative	for	endocarditis.	Besides	an	arthritis	of	his	right	knee	18F‐FDG‐PET/CT	also	showed	a	mycotic	
aneurysm	of	the	celiac	trunk	(arrows)	and	multiple	small	abscesses	in	liver	and	spleen.	This	patient	
underwent	a	surgical	repair	of	the	celiac	trunk	and	was	successfully	treated	with	flucloxacillin	intravenously	
for	six	weeks	after	surgery.		
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FIGURE	2.	18F‐FDG‐PET/CT	images	of	a	84‐year‐old	woman	with	a	right‐sided	closed	humerus	fracture	after	a	
fall.	Two	weeks	later	she	developed	arthritis	of	her	left	metacarpophalangeal	joints	and	blood	cultures	were	
positive	for	methicillin‐susceptible	Staphylococcus	aureus.	Transesophageal	echocardiography	was	negative	
for	endocarditis.	Besides	arthritis	of	her	left	metacarpophalangeal	joints	18F‐FDG‐PET/CT	also	showed	
metastatic	infection	in	her	right	hip	prosthesis,	left	ankle,	right	humerus	with	surrounding	abscesses,	and	
lumbar	spine	(L4‐L5)	with	a	right	psoas	abscess.	This	patient	underwent	CT‐guided	drainage	of	the	psoas	
abscess	and	was	treated	with	cephazolin,	because	of	allergy	to	flucloxacillin.		
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FIGURE	3.	18F‐FDG‐PET/CT	images	in	combination	with	contrast‐enhanced	CT	images	(lower‐left	panel)	of	a	
75‐year‐old	man	with	a	medical	history	of	COPD,	a	right	femoropopliteal	bypass	and	aortobifemoral	bypass	
who	was	admitted	because	of	fever.	Blood	cultures	were	positive	for	methicillin‐susceptible	Staphylococcus	
aureus.	Transesophageal	echocardiography	was	negative	for	endocarditis.	18F‐FDG‐PET/CT	showed	an	
infected	right	iliac	vascular	prosthesis.	This	patient	was	treated	with	antibiotic	therapy	for	5	months	and	
because	of	extensive	infection	he	finally	underwent	vascular	surgery.		
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TABLES	
TABLE	1.	Baseline	characteristic	of	all	184	patients	with	SAB		
	 Number	of	patients	(%)	
Total	 184		
Male	 113	(61.4)	
Mean	age	(range)	 61.1	(18‐80)	
Risk	factors	 	
‐	Community	acquisition		 120	(65.2)	
‐	Treatment	delay	>48h	 45	(28.1)	*	
‐	Persistent	fever	 54	(30.7)	†	
‐	Persistent	positive	blood	cultures	 39	(21.2)	
Rifampin	treatment	 48	(26.1)	
ID	specialist	bedside	consultation	 140	(76.1)	
Additional	risk	factors	 	
‐	Charlson	comorbidity	score	 4.7	
‐	Diabetes	mellitus	 42	(22.8)	
‐	Metastatic	malignancy	 16	(8.7)	
‐	Immunocompromised	 61	(33.2)	
‐	Joint	prosthesis	 26	(14.1)	
‐	Heart	valve	prosthesis	 23	(12.5)	
‐	Vascular	prosthesis	 20	(10.9)	
‐	Pacemaker/ICD	 18	(9.8)	
‐	Intravascular	catheter	 35	(19.0)	
‐	Total	parenteral	nutrition	 19	(10.3)	
TTE	 104	(56.5)	
TEE	 64	(34.8)	
TTE/TEE	 123	(66.8)	
ID:	Infectious	Disease;	ICD:	Implantable	Cardioverter	Defibrillator;	TTE:	transthoracic	echocardiography;	TEE:	
transesophageal	echocardiography;	*	No	data	available	in	24	patients;	†	No	data	available	in	8	patients	
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TABLE	2.	Localization	of	metastatic	foci	and	number	of	foci	first	detected	by	18F‐FDG‐PET/CT	in	99	high‐risk	
SAB	patients		
Metastatic	foci	identified	 Total	 First	detected	by	18F‐FDG	
PET/CT	(%)	
Vertebral	osteomyelitis/spondylodiscitis	 14	 8	(57.1)	
Arthritis	or	joint	prosthesis	 19	 7	(36.8)	
Non	vertebral	osteomyelitis	 10	 4	(40.0)	
Skin	and	soft	tissue	 31	 20	(64.5)	
Psoas	abscess	 7	 3	(42.9)	
Lung	 31	 17	(54.8)	
Spleen	 5	 5	(100.0)	
Liver/gallbladder	 3	 2	(66.7)	
Kidney	 1	 1	(100.0)	
Endocarditis	 18	 11(61.1)	
Endovascular	infection	(excluding	endocarditis)	 20	 15	(75.0)	
Pericarditis	or	mediastinitis	 4	 3	(75.0)	
Total	 164	 97	(59.1)	
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TABLE	3.	Characteristics	of	patients	with	≥1	risk	factor	for	metastatic	infection	in	whom18F‐FDG‐PET/CT	was	
performed	(PET+)	or	not	(PET‐)	
PET‐	
n	=	49	(%)	
PET+	
n	=	99	(%)	
p‐value	
Male	 32	(65.3)	 60	(60.6)	 0.579	
Mean	age	(SD)	 60.33	(14.2)	 60.61	(16.3)	 0.714	
Risk	factors	 	 	 	
Treatment	delay	>48	hours*		 9	(22.0)	 36	(43.4)	 0.020	
Fever	>72	hours	after	treatment	initiation†	 13	(27.7)	 43	(45.3)	 0.043	
Persistent	positive	blood	cultures	>48	hours	after	
treatment	initiation‡	
7	(15.6)	 32	(32.7)	 0.033	
Community	acquired	bacteremia	 31	(63.3)	 88	(88.9)	 <0.001	
Foreign	body	material	present	 15	(30.6)	 46	(46.5)	 0.065	
Infectious	disease	specialist	consultation	 30	(61.2)	 89	(89.9)	 <0.001	
Echocardiograpy§		 20	(40.8)	 90	(90.9)	 <0.001	
Charlson	comorbidity	score	(SD)	 5.12	(3.4)	 4.43	(2.9)	 0.314	
Intensive	care	admission	 14	(28.6)	 26	(26.3)	 0.766	
Three‐month	outcome	 	 	 	
							Death	 16	(32.7)	 12	(12.1)	 0.003	
							Recurrent	infection	 0	 3	(3.0)	 0.560	
Percentage	for	each	variable	is	indicated	in	brackets,	unless	otherwise	specified		
*	No	data	available	in	16	patients	
†	No	data	available	in	7	patients	
‡	No	follow‐up	blood	cultures	performed	in	5	patients	
§	Either	transthoracic	echocardiography	or	transesophageal	echocardiography	
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TABLE	4.	Univariate	and	multivariate	analysis	of	risk	factors	for	three‐month	mortality	in	patients	with	≥1	
risk	factor	for	metastatic	infection	(n=148)	
	 Alive	at	3	
months	
follow‐up	
(n=120)	
Death	at	3	
months	
follow‐up	
(n=28)	
Univariate	
analysis	
p‐value	
Multivariate	
analysis		
	p‐value	
OR	(95%	CI)	in	
multivariate	analysis	
Male		 67	(60.8)	 19	(67.9)	 0.490	 	 	
Echocardiography	
performed		
91	(75.8)	 19	(67.9)	 0.384	 	 	
Composite	risk	score*	
(SD)	
1.65	(1.14)	 1.93	(1.09)	 0.067	 0.052	 1.537	(0.997‐2.371)	
Charlson	comorbidity	
score	(SD)	
4.24	(2.90)	 6.46	(3.49)	 0.002	 0.003	 1.254	(1.078‐1.457)	
18F‐FDG‐PET/CT	
performed		
87	(72.5)	 12	(42.9)	 0.003	 0.005	 0.204	(0.066‐0.624)	
ID	specialist	
consultation	
99	(82.5)	 20	(71.4)	 0.184	 0.786	 0.851	(0.266‐2.721)	
ICU	admission	 29	(24.2)	 11	(39.3)	 0.105	 0.125	 2.147	(0.809‐5.698)	
Percentage	for	each	variable	is	indicated	in	brackets,	unless	otherwise	specified		
ICU:	Intensive	Care	Unit	
ID:	infectious	disease	
*	Composite	risk	score:	community‐acquisition,	persistent	fever	>72	hours,	and	skin	findings	suggesting	the	
presence	of	metastatic	infection	were	separately	scored	as	1	point,	and	positive	follow‐up	blood	culture	
results	were	scored	as	2	points	(3).		 	
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TABLE	5.	Treatment	modifications	in	99	patients	with	high‐risk	SAB	based	on	18F‐FDG‐PET/CT	results		
Treatment	modification	 n	(%)		
1) Extension	of	treatment	 	
a) Prolonged	intravenous	antibiotic	therapy	 15	(15.2)	
b) Addition	of	a	second	antimicrobial	drug	 10	(10.1)	
c) Extension	of	treatment	duration	 35	(35.3)	
2) Surgical	or	radiological	intervention	 19	(19.2)	
3) Shortening	of	treatment	duration	 25	(25.3)	
No	treatment	modification	 25	(25.3)	
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